CONTRIBUTORS

Sleep Neurology p. 941-947 August 2017, Vol.23, No.4 doi: 10.1212/01.CON.0000522239.75665.42
CONTRIBUTORS
BROWSE ARTICLES

Erik K. St. Louis, MD, MS, FAAN, FAASM, Guest Editor

Co-director, Mayo Center for Sleep Medicine; Associate Professor of Neurology; Consultant in Medicine and Neurology; Director, Sleep and Cognitive Neurophysiology Laboratory, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

aDr St. Louis serves on the editorial boards of Continuum and the Sleep and Chronobiology section of Frontiers in Neurology. Dr St. Louis has received personal compensation for serving as a consultant in clinical trial design for Axovant Sciences Ltd; for serving on the data safety monitoring board of Inspire Medical Systems, Inc; and has received research/grant support from Axovant Sciences Ltd; Mayo Clinic Center for Clinical and Translational Science; the Michael J. Fox Foundation; the National Institutes of Health/National Heart, Lung, and Blood Institute; and Sunovion Pharmaceuticals Inc. Dr St. Louis has received royalties from Wiley-Blackwell for the book, Epilepsy and the Interictal State: Co-morbidities and Quality of Life.

bDr St. Louis discusses the off-label use of clonazepam and melatonin for the treatment of rapid eye movement sleep behavior disorder.

Alon Y. Avidan, MD, MPH, FAAN

Professor, Vice Chair, Department of Neurology; Director, University of California Los Angeles Sleep Disorders Center, University of California Los Angeles, Los Angeles, California

aDr Avidan has received personal compensation for serving as a speaker for Arbor Pharmaceuticals and PERNIX Therapeutics and receives royalties from Elsevier and UpToDate, Inc.

bDr Avidan discusses the off-label use of various central nervous system–acting medications for insomnia, which include sedating antidepressants such as amitriptyline, doxepin, mirtazapine, and trazodone; the antipsychotic quetiapine; antihistamine compounds such as doxylamine; medications available over-the-counter marketed as sleep aids as single compounds or as a combination therapy with analgesics (acetaminophen or ibuprofen); and dietary supplement sleep aids such as chamomile, hops, kava kava, melatonin, passionflower, tart cherry juice, and valerian.

Lucie Barateau, MD

Neurologist, Sleep-Wake Disorders Center, National Reference Center for Narcolepsy and Idiopathic Hypersomnia, Gui de Chauliac Hospital, University of Montpellier, INSERM U1061, Montpellier, France

aDr Barateau has received reimbursement for travel expenses from Laidet Médical and has received personal compensation as a speaker for UCB SA.

bDr Barateau reports no disclosure.

Yves Dauvilliers, MD, PhD

Professor of Neurology and Physiology, Department of Neurology; Director of Sleep Lab; Coordinator, National Reference Center for Narcolepsy and Idiopathic Hypersomnia, Gui de Chauliac Hospital, University of Montpellier, INSERM U1061, Montpellier, France

aDr Dauvilliers has received personal compensation for speaking engagements and travel expenses, served as consultant for, and received research/grant support from Bioprojet Pharma, Flamel Technologies, Jazz Pharmaceuticals, Theranexus, and UCB SA. Dr Dauvilliers serves as specialty chief editor of the Sleep and Chronobiology section of Frontiers in Neurology.

bDr Dauvilliers reports no disclosure.

Mark Eric Dyken, MD, FAHA, FAASM, FANA

Professor of Neurology; Director of Sleep Disorders Program; Director of Clinical Neurophysiology Fellowship Program, Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, Iowa

a,bDr Dyken reports no disclosures.

Waleed Hamed El-Feky, MD

Neurologist; Director, Texas Neurology, Sleep Disorders Center, Dallas, Texas

a,bDr El-Feky reports no disclosures.

David A. Evans, MBA

Chief Executive Officer, Texas Neurology, Dallas, Texas

a,bMr Evans reports no disclosures.

Nancy R. Foldvary-Schaefer, DO, MS

Professor of Medicine, Department of Neurology, Cleveland Clinic Lerner College of Medicine; Director, Cleveland Clinic Sleep Disorders Center, Cleveland, Ohio

aDr Foldvary-Schaefer has received personal compensation for serving on the speaker’s bureau of Jazz Pharmaceuticals; receives research funding from Cleveland Medical Devices, Inc and UCB, Inc; and receives book royalties from Oxford University Press.

bDr Foldvary-Schaefer reports no disclosure.

Birgit Högl, MD

Associate Professor of Neurology; Director, Sleep Laboratory and Sleep Disorders Outpatient Unit, Medical University of Innsbruck, Innsbruck, Austria

aDr Högl serves as associate editor of the Journal of Clinical Sleep Medicine and receives personal compensation for serving on the advisory board of Mundipharma and UCB. Dr Högl has received honoraria for lectures for Abbvie, Eli Lilly and Company, Janssen Cilag, Lundbeck, Mundipharma, Otsuka Pharmaceutical, and UCB, and as a consultant for Axovant and Benevolent Bio. Dr Högl receives royalties from Cambridge University Press and Springer.

bDr Högl discusses the unlabeled/investigational use of clonazepam and melatonin for the management of rapid eye movement sleep behavior disorder.

Richard L. Horner, PhD

Professor of Medicine and Physiology; Canada Research Chair, University of Toronto, Toronto, Ontario, Canada

aDr Horner has received personal compensation for serving as a consultant for Dairy Farmers of Canada and Viord Inc and receives royalties from BookBaby for his book, The Universal Pastime: Sleep and Rest Explained. Dr Horner has received grants from Canada Research Chair (950-229813), the Canadian Institutes of Health Research (MT-15563), and the National Sanitarium Association Innovative Research Program (00144051).

bDr Horner reports no disclosure.

Michael J. Howell, MD, FAAN

Associate Professor; Vice Chair of Education, Department of Neurology, University of Minnesota, Minneapolis, Minnesota

aDr Howell serves as an associate editor for MedLink.com and has received personal compensation for speaking engagements from the Sleep Performance Institute. Dr Howell receives royalties from UpToDate, Inc and research/grant support from the National Institutes of Health.

bDr Howell discusses the unlabeled/investigational use of benzodiazepines and melatonin for the treatment of parasomnias.

Alex Iranzo, MD

Neurologist, Hospital Clínic de Barcelona; Associate Professor, University of Medicine, Universidad de Barcelona, Barcelona, Spain

aDr Iranzo has received personal compensation for serving on the advisory board of and as a lecturer for Otsuka Pharmaceutical and UCB.

bDr Iranzo discusses the unlabeled/investigational use of clonazepam and melatonin for the management of rapid eye movement sleep behavior disorder.

Muna Irfan, MD

Assistant Professor, Department of Neurology, Hennepin County Medicine Center, University of Minnesota, Minneapolis, Minnesota

aDr Irfan reports no disclosure.

bDr Irfan discusses the unlabeled/investigational use of benzodiazepines and melatonin for the treatment of parasomnias.

Yo-El S. Ju, MD, MSCI

Assistant Professor of Neurology, Department of Neurology, Sleep Medicine Section, Washington University in St. Louis, St. Louis, Missouri

aDr Ju has received personal compensation for serving as a speaker and moderator for the American Academy of Neurology, as a speaker for the American Academy of Sleep Medicine and the World Association of Sleep Medicine, and as a consultant of C2N Diagnostics. Dr Ju has received research/grant support from the National Institutes of Health and as principal investigator of a study for Philips Respironics.

bDr Ju discusses the unlabeled/investigational use of trazodone to treat comorbid sleep disturbances in dementia.

Suresh Kotagal, MD, FAAN

Professor, Department of Neurology; Consultant in Neurology, Pediatrics, and Sleep Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

aDr Kotagal has received personal compensation as chair of the data safety monitoring board for INC Research, Inc and receives royalties from UpToDate, Inc.

bDr Kotagal reports no disclosure.

David N. Neubauer, MD

Associate Professor, Johns Hopkins University School of Medicine, Baltimore, Maryland

aDr Neubauer has received personal compensation for serving on the board of directors for the National Sleep Foundation, as a consultant for Purdue Pharma LP, and as a lecturer for the American Academy of Sleep Medicine, the American College of Chest Physicians, the Clayton Sleep Institute, the New Jersey Sleep Society, and the US Psychiatric and Mental Health Congress.

bDr Neubauer discusses the off-label use of various central nervous system–acting medications for insomnia, which include sedating antidepressants such as amitriptyline, doxepin, mirtazapine, and trazodone; the antipsychotic quetiapine; antihistamine compounds such as doxylamine; medications available over-the-counter marketed as sleep aids as single compounds or as a combination therapy with analgesics (acetaminophen or ibuprofen); and dietary supplement sleep aids such as chamomile, hops, kava kava, melatonin, passionflower, tart cherry juice, and valerian.

Milena Pavlova, MD, FAASM

Medical Director, Sleep Testing Center, Department of Neurology, Brigham and Women’s Faulkner Hospital; Assistant Professor, Harvard Medical School, Harvard University, Boston, Massachusetts

aDr Pavlova serves as associate editor of the Sleep and Chronobiology section of Frontiers in Neurology and receives research/grant support from Biomobie Inc and Lundbeck.

bDr Pavlova reports no disclosure.

John H. Peever, PhD

Professor, University of Toronto, Toronto, Ontario, Canada

aDr Peever has received grant support from the Canadian Institutes of Health Research.

bDr Peever reports no disclosure.

Michael Rubin, MD, MA

Assistant Professor of Neurology and Neurotherapeutics, Assistant Professor of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas

a,bDr Rubin reports no disclosures.

Carlos H. Schenck, MD

Professor, Department of Neurology, Hennepin County Medicine Center, University of Minnesota, Minneapolis, Minnesota

aDr Schenck has received personal compensation as a consultant for Sunovion Pharmaceuticals, Inc.

bDr Schenck discusses the unlabeled/investigational use of benzodiazepines and melatonin for the treatment of parasomnias.

Michael H. Silber, MBChB, FAAN

Professor of Neurology, Mayo Clinic College of Medicine and Science; Consultant Neurologist, Mayo Clinic Center for Sleep Medicine in Minnesota, Rochester, Minnesota

aDr Silber receives royalties from Oakstone Publishing and UpToDate, Inc.

bDr Silber reports no disclosure.

Jon Tippin, MD, FAAN, FAASM

Clinical Professor of Neurology, Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa

aDr Tippin received research/grant support from the National Institutes of Health/National Heart, Lung, and Blood Institute (R01 HL091917-01A2).

bDr Tippin reports no disclosure.

Lynn Marie Trotti, MD, MSc

Associate Professor of Neurology; Associate Director, Sleep Medicine Fellowship, Emory University School of Medicine, Atlanta, Georgia

aDr Trotti serves on the editorial board of the Journal of Clinical Sleep Medicine and has received personal compensation as a speaker for the American Academy of Neurology, Associated Professional Sleep Societies, Movement Disorder Society, New Jersey Sleep Society, New York University, Ohio State University, and Southern Sleep Society. Dr Trotti has received research/grant support from the National Institute of Neurological Disorders and Stroke and the National Institutes of Health (K23 NS083748).

bDr Trotti discusses the unlabeled/investigational use of benzodiazepines, botulinum toxin, clonazepam, and clonidine for the treatment of bruxism; of clonazepam for the treatment of hypnic myoclonus and rhythmic movement disorder; of carbamazepine, carisoprodol, diltiazem, gabapentin, lamotrigine, magnesium, oxcarbazepine, quinine, and verapamil for the treatment of leg cramps; of clonazepam and topiramate for the treatment of propriospinal myoclonus; and of gabapentin, iron (including ferric carboxymaltose), opioids, and pregabalin for the treatment of restless legs syndrome.

Bradley V. Vaughn, MD, FAAN, FAASM

Professor of Neurology, University of North Carolina School of Medicine, University of North Carolina, Chapel Hill, North Carolina

aDr Vaughn has received personal compensation as a speaker for the American Academy of Neurology, American Academy of Sleep Medicine, and Medical Education Resources and receives royalties from Medlink Neurobase and UpToDate, Inc. Dr Vaughn has received personal compensation for serving as chair of the sleep medicine examination committee of the American Board of Internal Medicine.

bDr Vaughn reports no disclosure.

Aleksandar Videnovic, MD, MSc, FAAN, FAASM

Associate Professor of Neurology, Harvard Medical School, Harvard University; Director, Program on Sleep, Circadian Biology and Neurodegeneration, Massachusetts General Hospital, Boston, Massachusetts

aDr Videnovic serves on the editorial board of Parkinsonism & Related Disorders and has received personal compensation for serving as chair of the data and safety monitoring board of Acorda Therapeutics and for serving on the data and safety monitoring board of Wilson Therapeutics. Dr Videnovic has received research grants from the National Institute of Neurological Disorders and Stroke and receives royalties from Springer International Publishing AG.

bDr Videnovic reports no disclosure.

Tina E. Waters, MD

Neurologist, Sleep Disorders Center; Clinical Assistant Professor, Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio

aDr Waters receives research funding as principal investigator for a study for the Inspire Upper Airway Stimulation therapy system through Inspire Medical Systems, Inc.

bDr Waters reports no disclosure.

Ronnie Bergen, MD

Assistant Professor of Clinical Neurology, University of Arizona; Staff Neurologist, Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona

a,bDr Bergen reports no disclosures.

James W. M. Owens Jr, MD, PhD

Associate Professor of Neurology and Adjunct Associate Professor of Pediatrics, University of Washington, Seattle, Washington

aDr Owens receives personal compensation for medicolegal record review and royalties from UpToDate, Inc.

bDr Owens reports no disclosure.

Copyright © 2017 by the American Academy of Neurology.